TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07608432: Efficacy, Safety, and Tolerability of Zeleciment Rostudirsen (DYNE-251) Administered Intravenously Every 4 Weeks in Ambulatory Participants With Duchenne Muscular Dystrophy (FORZET

Sponsor: Dyne Therapeutics · Phase: PHASE3 · Area: RARE_ORPHAN · Target Enrollment: 90 pts

Competing Trials Overlap

3 Active Trials

Excess Burn Exposure

$23,401,600

Rescue Site Savings

+$15,430,430

Unlock Full NCT07608432 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07608432 Rescue Dossier →